Merck and Palantir Technologies to form a joint venture.

Merck, a science and technology company, and Palantir Technologies, a software company, to form a joint venture under the brand name Syntropy. Financial terms were not disclosed. Syntropy is expected to empower scientists and research centers with a collaborative technology platform to advance cancer research, help drive scientific discovery, and improve human lives. “Unlocking the power of scientific data is critical to advancing the fight against cancer. Syntropy aims to help researchers collaborate securely to realize the value of this data, driving discoveries that will deliver better treatments to patients faster," Alexander Karp, Palantir Co-Founder and CEO.